J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta – Reuters India
Johnson & Johnson on Wednesday agreed to pay about $6.5 billion in cash to buy Momenta Pharmaceuticals Inc in a deal aimed at expanding its portfolio of autoimmune disease treatments.
